Interrelationships Between Serum Levels of Procalcitonin and Inflammatory Markers in Patients Who Visited a General Medicine Department.
bacterial infection
inflammation
malignant lymphoma
procalcitonin
soluble interleukin-2 receptor
Journal
Acta medica Okayama
ISSN: 0386-300X
Titre abrégé: Acta Med Okayama
Pays: Japan
ID NLM: 0417611
Informations de publication
Date de publication:
Jun 2021
Jun 2021
Historique:
entrez:
28
6
2021
pubmed:
29
6
2021
medline:
15
12
2021
Statut:
ppublish
Résumé
Various laboratory markers of inflammation are utilized in general practice, but their clinical diagnostic significance is often ambiguous. In the present study, we determined the clinical significance of the examination of serum levels of procalcitonin (PCT) by comparing the PCT levels with the levels of other inflammatory markers, based on a retrospective review of 332 PCT-positive patients, including cases of bacterial infection (20.5%), non-specific inflammation (20.8%), neoplasm (9.9%), connective tissue diseases (8.4%), and non-bacterial infection (7.2%), were analyzed. The serum PCT level was highest in the bacterial infection group (1.94 ng/ml) followed by the non-specific inflammatory group (0.58 ng/ml) and neoplastic diseases group (0.34 ng/ml). The serum PCT level was positively correlated with serum levels of C-reactive protein (rho=0.62), soluble interleukin-2 receptor (sIL-2R; rho=0.69), and ferritin, the plasma level of D-dimer, and white blood cell count, and negatively correlated with the serum albumin level (rho=-0.52), hemoglobin concentration, and platelet count. The serum PCT level showed a stronger positive correlation with the serum sIL-2R level than the other biomarkers. The results suggest that an increased PCT level may indicate not only an infectious state but also a non-bacterial inflammatory condition in the diagnostic process in general practice.
Substances chimiques
Biomarkers
0
Procalcitonin
0
C-Reactive Protein
9007-41-4
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
299-306Déclaration de conflit d'intérêts
No potential conflict of interest relevant to this article was reported.
Références
Assicot M, Gendrel D, Carsin H, Raymond J, Guilbaud J and Bohuon C: High serum procalcitonin concentrations in patients with sepsis and infection. Lancet (1993) 341: 515-518.
Castelli GP, Pognani C, Meisner M, Stuani A, Bellomi D and Sgarbi L: Procalcitonin and C-reactive protein during systemic inflammatory response syndrome, sepsis and organ dysfunction. Crit Care (2004) 8: R234-242.
Jensen JU, Heslet L, Jensen TH, Espersen K, Steffensen P and Tvede M: Procalcitonin increase in early identification of critically ill patients at high risk of mortality. Crit Care Med (2006) 34: 2596-2602.
Nobre V, Harbarth S, Graf JD, Rohner P and Pugin J: Use of procalcitonin to shorten antibiotic treatment duration in septic patients: a randomized trial. Am J Respir Crit Care Med (2008) 177: 498-505.
Christ-Crain M, Stolz D, Bingisser R, Muller C, Miedinger D, Huber PR, Zimmerli W, Harbarth S, Tamm M and Muller B: Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia: a randomized trial. Am J Respir Crit Care Med (2006) 174: 84-93.
Stolz D, Christ-Crain M, Bingisser R, Leuppi J, Miedinger D, Muller C, Huber P, Muller B and Tamm M: Antibiotic treatment of exacerbations of COPD: a randomized, controlled trial comparing procalcitonin-guidance with standard therapy. Chest (2007) 131: 9-19.
Christ-Crain M, Jaccard-Stolz D, Bingisser R, Gencay MM, Huber PR, Tamm M and Muller B: Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single-blinded intervention trial. Lancet (2004) 363: 600-607.
Morgenthaler NG, Struck J, Fischer-Schulz C, Seidel-Mueller E, Beier W and Bergmann A: Detection of procalcitonin (PCT) in healthy controls and patients with local infection by a sensitive ILMA. Clin Lab (2002) 48: 263-270.
Muller B, Becker KL, Schachinger H, Rickenbacher PR, Huber PR, Zimmerli W and Ritz R: Calcitonin precursors are reliable markers of sepsis in a medical intensive care unit. Crit Care Med (2000) 28: 977-983.
Harbarth S, Holeckova K, Froidevaux C, Pittet D, Ricou B, Grau GE, Vadas L, Pugin J and Geneva Sepsis N: Diagnostic value of procalcitonin, interleukin-6, and interleukin-8 in critically ill patients admitted with suspected sepsis. Am J Respir Crit Care Med (2001) 164: 396-402.
Meisner M, Adina H and Schmidt J: Correlation of procalcitonin and C-reactive protein to inflammation, complications, and outcome during the intensive care unit course of multiple-trauma patients. Crit Care (2006) 10: R1.
Oka K, Hanayama Y, Sato A, Omura D, Yasuda M, Hasegawa K, Obika M and Otsuka F: Clinical Characteristics of Febrile Outpatients: Possible Involvement of Thyroid Dysfunction in Febrile Tachycardia. Acta Med Okayama (2018) 72: 447-456.
Omura D, Sato A, Oka K, Hanayama Y, Ogawa H, Obika M and Otsuka F: Changes in Serum Biochemical Markers in Relation to Chief Complaints and Aging in General Medicine. Acta Med Okayama (2018) 72: 553-562.
Kanda Y: Investigation of the freely available easy-to-use software ʻEZRʼ for medical statistics. Bone Marrow Transplant (2013) 48: 452-458.
Ryuko H and Otsuka F: A comprehensive analysis of 174 febrile patients admitted to Okayama University Hospital. Acta Med Okayama (2013) 67: 227-237.
Hoffmann C, Hoffmann P and Zimmermann M: Diagnostic testing for a high-grade inflammation: parameter dynamics and novel markers. Clin Chem Lab Med (2015) 53: 541-547.
Felder S, Braun N, Stanga Z, Kulkarni P, Faessler L, Kutz A, Steiner D, Laukemann S, Haubitz S, Huber A, Mueller B and Schuetz P: Unraveling the Link between Malnutrition and Adverse Clinical Outcomes: Association of Acute and Chronic Malnutrition Measures with Blood Biomarkers from Different Pathophysiological States. Ann Nutr Metab (2016) 68: 164-172.
Murakami S: Soluble interleukin-2 receptor in cancer. Front Biosci (2004) 9: 3085-3090.
Lin M, Park S, Hayden A, Giustini D, Trinkaus M, Pudek M, Mattman A, Schneider M and Chen LYC: Clinical utility of soluble interleukin-2 receptor in hemophagocytic syndromes: a systematic scoping review. Ann Hematol (2017) 96: 1241-1251.
Dehne MG, Sablotzki A, Hoffmann A, Muhling J, Dietrich FE and Hempelmann G: Alterations of acute phase reaction and cytokine production in patients following severe burn injury. Burns (2002) 28: 535-542.
Llewelyn MJ, Berger M, Gregory M, Ramaiah R, Taylor AL, Curdt I, Lajaunias F, Graf R, Blincko SJ, Drage S and Cohen J: Sepsis biomarkers in unselected patients on admission to intensive or high-dependency care. Crit Care (2013) 17: R60.
Garcia de Guadiana-Romualdo L, Berger M, Jimenez-Santos E, Rebollo-Acebes S, Jimenez-Sanchez R, Esteban-Torrella P, Hernando-Holgado A, Ortin-Freire A and Albaladejo-Oton MD: Pancreatic stone protein and soluble CD25 for infection and sepsis in an emergency department. Eur J Clin Invest (2017) 47: 297- 304.
Urbonas V, Eidukaite A and Tamuliene I: The predictive value of soluble biomarkers (CD14 subtype, interleukin-2 receptor, human leucocyte antigen-G) and procalcitonin in the detection of bacteremia and sepsis in pediatric oncology patients with chemotherapy- induced febrile neutropenia. Cytokine (2013) 62: 34-37.
Garcia de Guadiana-Romualdo L, Jimenez-Santos E, Cerezuela- Fuentes P, Espanol-Morales I, Berger M, Esteban-Torrella P, Hernando-Holgado A and Albaladejo-Oton MD: Analyzing the capability of PSP, PCT and sCD25 to support the diagnosis of infection in cancer patients with febrile neutropenia. Clin Chem Lab Med (2019) 57: 540-548.